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Introduction: KRAS mutations are present in 30% of lung adeno-
carcinomas. Salirasib prevents Ras membrane binding thereby
blocking the function of all Ras isoforms. This phase II study
determined the activity of salirasib in patients with advanced lung
adenocarcinomas with KRAS mutations.
Methods: Two cohorts of patients with stage IIIB/IV lung ade-
nocarcinoma were eligible: patients with tumors with KRAS
mutations who were previously treated with chemotherapy and
patients receiving initial therapy who had 15 pack-year smok-
ing history. Salirasib was given orally from days 1 to 28 of a
35-day cycle. The primary end point was the rate of nonprogres-
sion at 10 weeks.
Results: Thirty-three patients were enrolled. Thirty patients had
KRAS mutations (23 patients who were previously treated and
7/10 patients who had no prior therapy). Of the previously treated
patients, 7 of 23 (30%) had stable disease at 10 weeks, and 4 of
10 (40%) previously untreated patients had stable disease at 10
weeks. No patient had a radiographic partial response (0%
observed rate, 95% confidence interval 0 –12%). The median
overall survival was not reached (9 months) for previously
untreated patients and it was 15 months for patients who received
prior chemotherapy. Diarrhea, nausea, and fatigue were the most
common toxicities.
Conclusions: Salirasib at the current dose and schedule has insuf-
ficient activity in the treatment of KRAS mutant lung adenocarci-
noma to warrant further evaluation. The successful enrollment of 30
patients with tumors with KRAS mutant lung adenocarcinoma over
15 months at a single site demonstrates that drug trials directed at a
KRAS-specific genotype in lung cancer are feasible.
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KRAS is an oncogene that is mutated in approximately 30%of lung adenocarcinomas diagnosed in the United States.
This oncogene encodes one of three isoforms of Ras (N-Ras,
K-Ras, and H-Ras) which, when mutated, lead to tumor
formation. Somatic KRAS mutations in non-small cell lung
cancer (NSCLC) were identified more than 25 years ago.1
KRAS mutations are more common in lung adenocarcinomas
from patients with a heavy cigarette smoking history, but
they also occur in patients who never smoked cigarettes.2
KRAS mutations predict absence of response to gefitinib
and erlotinib in lung cancer.3 The value of KRAS mutations
as a predictive and prognostic factor in NSCLC has not
been thoroughly evaluated in the context of other known
risk factors.4
Ras signaling leads to activation of effector pathways
which causes cellular proliferation, survival, and alteration of
gene expression (reviewed in Ref. 5). Point mutations in Ras
lead to loss of GTPase activity resulting in constitutive
signaling. In animal models, expression of mutant KRAS
leads to tumor formation.6,7 In such models, continued ex-
pression of mutant KRAS is necessary for tumor maintenance
as evidenced by apoptosis and tumor regression when mutant
KRAS is no longer expressed. This requirement for continued
Ras activation for tumor maintenance makes it a target for
anticancer drugs.
Salirasib (s-trans, trans-farnesylthiosalicylic acid) de-
creases the activity of activated Ras by competitively inhib-
iting the attachment of GTP-bound Ras to the plasma mem-
brane.8 By preventing membrane binding, Ras signaling is
blocked. Salirasib inhibits all isoforms of Ras in contrast to
farnesyltransferase inhibitors, which fail to inhibit K-Ras and
N-Ras function due to alternative membrane-binding mecha-
nisms.9 Salirasib has been shown to reduce tumor growth and
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total cell K-Ras levels in A549, H1299, and HTB54 as both a
single agent and in combination with chemotherapy.10,11
In a phase I trial, salirasib dosing was evaluated in
patients with advanced cancers and neurofibromatosis.12 The
most commonly observed toxicities were diarrhea (grades
1–2, present in 79% of patients), fatigue, nausea, and vom-
iting. In the absence of grade 3 or 4 dose-limiting toxicities,
dose escalation was discontinued at 800 mg twice daily (on
days 1–21 of a 28-day cycle) because of persistent grades 1 to
2 diarrhea, making this the maximum tolerated dose. No
patients with lung cancer were treated in the phase I trial.
We hypothesized that salirasib would prevent tumor
growth or lead to tumor shrinkage in patients with KRAS
mutant lung adenocarcinoma. We conducted this phase II
trial to assess the efficacy of single-agent salirasib as the
initial treatment of lung adenocarcinoma and in patients with
KRAS mutations who had been previously treated with che-
motherapy. Patients with previously untreated lung adenocar-
cinoma were limited to those patients with a smoking history
of 15 pack-years to reduce the frequency of patients with
epidermal growth factor receptor mutations in this cohort.13
PATIENTS AND METHODS
Eligibility
Patients with stage IIIB or IV lung adenocarcinoma
with measurable disease by RECIST were candidates for this
trial. Two groups of patients were eligible: previously un-
treated patients with lung adenocarcinoma with a smoking
history of 15 pack-years (previously untreated) or those
with a documented KRAS mutation and any number of prior
therapies (previously treated). Other eligibility criteria in-
cluded age 18 years or older, Karnofsky Performance Status
of 70% or greater, and adequate renal and hepatic function.
Patients with symptomatic or progressing central nervous
system metastases or who had received chemotherapy or
radiotherapy in the 3 weeks before starting therapy were
excluded. The clinical trial protocol and informed consent
were approved by the Memorial Sloan-Kettering Cancer
Center Institutional Review Board. All patients provided
written informed consent.
Study Evaluations and Drug Administration
A medical history, physical examination, complete
blood count, and comprehensive metabolic panel were mea-
sured within 2 weeks before study entry and at initiation of
each cycle of therapy (every 5 weeks). Patients were assessed
for toxicity based on National Cancer Institute Common
Toxicity Criteria for Adverse events, version 3.0. Objective
tumor responses were determined by imaging of all known
sites of disease less than 4 weeks before study entry, after 4
and 10 weeks of treatment, and then every 10 weeks there-
after using RECIST 1.0.
Patients were treated with salirasib 800 mg twice daily
on days 1 to 28 of a 35-day cycle. The schedule of days 1 to
28 of a 35-day cycle was chosen to allow initial imaging after
4 weeks of continual treatment. After 10 patients were en-
rolled, because of toxicity (described in Results), the initial
dose was changed to 600 mg twice daily.
Statistical Analysis
The primary end point was the rate of nonprogression
(RECIST complete response  partial response  stable
disease) at 10 weeks for patients treated with salirasib. Sec-
ondary end points included RECIST response rate, duration
of response, time to disease progression, and overall survival
for patients treated with salirasib. Sample size was deter-
mined for two groups of patients (patients previously treated
with known KRAS mutation and patients previously un-
treated). For patients who had been previously treated, a
Simon two-stage minmax design was chosen with an  
0.05,   0.2 with a null 10-week stable disease rate of 20%,
and an alternative stable disease rate of 40%. For this design,
initially 18 patients were to be enrolled and, if 5 or more
patients had 10-week stable disease, an additional 15 patients
were to be enrolled. For previously untreated patients, a
Simon two-stage minmax design was chosen with an  
0.05 and  0.1 for a null 10-week stable disease rate of 5%
and an alternative 10-week stable disease rate of 20%. A
lower alternative hypothesis response rate was chosen for this
group because KRAS mutation was not required for enroll-
ment. For this design, 29 patients were to be enrolled in stage
I. If one patient had stable disease at 10 weeks, then an
additional nine patients were to be enrolled. Although there
were no additional predefined stopping points for efficacy
analysis, in the absence of any radiographic partial responses,
further enrollment was discontinued after a total of 33 pa-
tients were enrolled.
RESULTS
Between August 2007 and December 2008, 33 patients
were enrolled and treated with salirasib. Baseline character-
istics are listed in Table 1.
Efficacy
Of previously treated patients, 7 of 23 (30%, 95%
confidence interval: 15–51%) had stable disease at 10 weeks
and 4 of 10 (40%, 95% confidence interval: 17–69%) previ-
ously untreated patients had stable disease at 10 weeks. Of
TABLE 1. Baseline Characteristics
Characteristic
Total
(n  33)
Previously
Untreated
(n  10)
Previously
Treated
(n  23)
Median age (range), yr 68 (46–82) 73 (64–79) 65 (46–82)
Sex
Female 20 7 13
Male 13 3 10
KRAS mutation
Yes 30 7 23
No 2 2 0
Unknown 1 1 0
Smoking history
Never 3 0 3
Former (15 pack-years) 4 0 4
Former (15 pack-years) 26 10 16
Prior lines of therapy, median (range) 1 (1–8) 0 2 (1–8)
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the 11 patients with nonprogression at 10 weeks, the median
time of stable disease was 7 months (range 5–25 months). No
patients had a radiographic partial response (Figure 1). As 30
of 33 patients had documented KRAS mutations, association
of KRAS mutation status and outcomes was not possible. The
median time to progression was 2 months for patients previ-
ously untreated and 1 month for patients previously treated
with chemotherapy. The median overall survival was not
reached (9 months) for previously untreated patients and 15
months for patients who had received prior chemotherapy.
Toxicity
Diarrhea, nausea, and fatigue were the most common
toxicities (Table 2). Three patients withdrew due to drug-
related diarrhea before completing 10 weeks of therapy.
Among the first 10 patients, 2 required a dose reduction
because of intolerable grade 2 diarrhea and 2 withdrew from
the study with grade 3 diarrhea. The remaining patients
enrolled in the study received 600 mg twice daily as the
starting dose. In total, 24% of patients had drug-related grade
3 adverse events (five patients with diarrhea, two patients
with grade 3 fatigue, and one patient with nausea). Four
patients had grade 3 dyspnea on study that was attributed to
disease progression. There were no grade 4 or 5 drug-related
adverse events.
DISCUSSION
In this study, we report a prospective phase II trial of
salirasib in patients with KRAS mutant NSCLC. Treatment
with salirasib was associated with modest toxicity (mostly
diarrhea), and no significant antitumor activity with no
partial responses observed. On the basis of these data,
salirasib monotherapy at the current dose and schedule
(days 1–28 of a 35-day cycle) has insufficient activity in
the treatment of KRAS mutant lung adenocarcinoma to
warrant further evaluation.
To our knowledge, this is the first report of a prospec-
tive clinical trial in patients with NSCLC that required doc-
umented KRAS mutation for inclusion. This clinical trial
accrued in a relatively short period of time (accruing 30
patients with KRAS mutant lung adenocarcinoma at a single
site in 15 months), demonstrating the feasibility of this
genotype-specific approach for evaluation of therapies for
patients with lung adenocarcinoma with KRAS mutations.
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FIGURE 1. Best response for indicator lesions (RECIST) for
individual patients.
TABLE 2. Toxicities During Salirasib Treatment
Grade
1
Grade
2
Grade
3
Grade
4 Total
Diarrhea 20 4 5 0 29
Nausea 16 1 1 0 18
Fatigue 9 7 2 0 18
Dyspnea 1 2 4 0 7
Rash 6 0 0 0 6
Cough 2 3 0 0 5
Constipation 4 0 0 0 4
Abdominal pain 3 0 0 0 3
Peripheral edema 3 0 0 0 3
Neuropathy 3 0 0 0 3
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